(NASDAQ:PRTK) gained 8.2% to close at $5.29. Immuron shares dipped over 15% on Thursday as the company said it will not proceed with proposed acquisition of R&D vaccine company.
(NASDAQ:EZFL) gained 14.5% to settle at $3.32. The company also announced acquisition of privately held Kemp for $258 million in cash.
ZACC KABUSHIKI SOFTWARE
Progress Software Corporation (NASDAQ:PRGS) climbed 14.9% to close at $53.10 as the company reported better-than-expected results for its third quarter and raised FY21 guidance.Achilles Therapeutics plc (NASDAQ:ACHL) surged 16.8% to close at $6.95.Marin Software recently announced a revenue share agreement with Google. Marin Software Incorporated (NASDAQ:MRIN) gained 19.6% to close at $10.21.Nisun International reported 1H sales of $38.9 million, up 188.9% year over year. Nisun International Enterprise Development Group Co., Ltd (NASDAQ:NISN) gained 19.9% to close at $11.56.
ZACC KABUSHIKI FULL
Metacrine recently said it achieved full enrollment for MET642 Phase 2a trial in patients with Nash. (NASDAQ:MTCR) gained 21.2% to close at $3.72. (NASDAQ:GOEV) climbed 21.8% to close at $9.04.
(NASDAQ:HLTH) gained 25% to settle at $20.00 after pricing its IPO at $16 a share. Meredith Corporation (NYSE:MDP) shares rose 25.4% to close at $56.30 following reports suggesting IAC/InterActiveCorp is in advanced talks to acquire the company in a deal valued at over $2.5 billion.(NASDAQ:FLGC) jumped 33.7% to close at $6.90. The company also said it sees FY21 revenue of $50 million. Aehr Test Systems (NASDAQ:AEHR) gained 34.3% to settle at $15.82 after the company reported better-than-expected Q1 results.Paltalk, last month, reported Q2 earnings of $0.12 per share. (NASDAQ:PALT) climbed 35.5% to settle at $4.01. Form 4 filings from late Thursday showed stock purchases from multiple company’s Directors. (NASDAQ:UFAB) gained 36.9% to close at $3.45. (NYSE:CWAN) surged 40.9% to settle at $25.37 after the company priced its IPO at $18 per share. (NASDAQ:ZIVO) shares climbed 58% to close at $5.45 on Friday. (NasdaqCM:MRM) completed the acquisition of ZACC Kabushiki-Kaisha from all of the existing shareholders of ZACC Kabushiki-Kaisha in January 2022. The second stage is scheduled to close on January 1, 2022. The first stage of the acquisition is scheduled to close on October 1, 2021.
At the second stage, the remaining shares of ZACC will be transferred to MEDIROM. In the first stage, the shareholders of ZACC will transfer 60% of the common shares of ZACC to MEDIROM. The purchase price will be paid by cash on hand, and an initial payment of ¥69,013,698 was made on August 31, 2021. MEDIROM Healthcare Technologies will acquire 100% of the shares of ZACC through a two-stage acquisition for total consideration of ¥370 million. (NasdaqCM:MRM) entered into a share transfer agreement to acquire ZACC Kabushiki-Kaisha from all of the existing shareholders of ZACC Kabushiki-Kaisha for ¥370 million on August 31, 2021.
0 kommentar(er)
